Trials / Recruiting
RecruitingNCT07383857
PULSAR Radiotherapy Plus Anti-PD-1 Therapy in Metastatic Abdominopelvic Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 103 (estimated)
- Sponsor
- Zhen Zhang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates hypofractionated radiotherapy combined with PD-1 inhibitor-based systemic therapy in patients with metastatic solid tumors. Eligible patients will be enrolled into three cohorts according to tumor type: metastatic hepatocellular carcinoma, metastatic renal cell carcinoma, and metastatic urothelial carcinoma. The study aims to assess the safety and therapeutic efficacy of combining localized radiotherapy with immunotherapy, with or without cohort-specific systemic agents.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | pulsed radiotherapy | All enrolled participants will receive pulsed radiotherapy (PULSAR) |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
- First posted
- 2026-02-03
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07383857. Inclusion in this directory is not an endorsement.